Dissecting Survival Pathways in Lung Cancer, Fibrosis and Emphysema: “The Four Horses of the Apocalypse”

Diagnostic and Therapeutic Challenges for Patients with Idiopathic Pulmonary Fibrosis and Lung Cancer

“…IPF and lung cancer share striking pathogenetic commonalities such as telomere attrition, microsatellite instability, epigenetic alterations and impaired cellular bioenergetics 2,[7][8][9][10] . In line with these, nintedanib, a triple kinase inhibitor, initially launched as an anti-cancer compound, was successfully repurposed for patients with IPF 9,[11][12][13][14][15][16][17] . Despite major advances, there is still a lack of high-quality prospective studies evaluating therapeutic interventions including antifibrotics in patients with IPF and concomitant lung cancer 2 .…”